Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05480683
Other study ID # 22-001770
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 4, 2022
Est. completion date August 2024

Study information

Verified date April 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out how including a CT exam of the penis can help urologists make treatment decisions for patients with calcified Peyronie's disease.


Description:

Peyronie disease (PD) affects up to 10% of men with fibrosing penile plaques causing penile pain and progressing to deformity. Calcified plaque develops in up to 20% of these patients, excluding them from medical therapy with collagenase injection and often requiring more extensive surgery for treatment. PDDU identifies plaque distribution and characteristics while the Doppler exam evaluates for any underlying erectile dysfunction. Calcification can make PDDU difficult to identify the full extent of plaque since the shadow caused by calcification may prevent accurate measurement and over or underestimate the plaque size. In addition, the ultrasound exam is operator dependent and requires injection of an agent to induce erection. Since current clinical practice excludes men with any degree of calcification presumed on physical examination or demonstrated on PDDU from receiving injection therapy they may be triaged to surgical management instead. A prior study found the presence of calcifications at ultrasound had odd ratio 1.75 of patient progressing to surgical management, while fibrosis without calcification did not have increased odds of surgical management. Noncontrast pelvis CT provides three dimensional detail of calcified plaque including parts of the penis that are difficult to image with PDDU, and calcification does not have artifact on CT. By adding non-contrast pelvis CT with Agatston calcium scoring to PDDU and clinical parameters of penile deformity, patients may be better stratified into the appropriate treatment pathway.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Peyronie Disease with stable curvature considered for therapeutic intervention - PDDU obtained at clinic visit - Able to provide informed consent Exclusion Criteria: - Implanted penile prosthesis or implanted urethral sphincter that would prevent adequate CT images - Acute active Peyronie disease that would not be managed with injection or surgical therapy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
CT exam
Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.

Locations

Country Name City State
United States Mayo Clinic Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

References & Publications (3)

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990 Mar 15;15(4):827-32. doi: 10.1016/0735-1097(90)90282-t. — View Citation

Breyer BN, Shindel AW, Huang YC, Eisenberg ML, Weiss DA, Lue TF, Smith JF. Are sonographic characteristics associated with progression to surgery in men with Peyronie's disease? J Urol. 2010 Apr;183(4):1484-8. doi: 10.1016/j.juro.2009.12.026. Epub 2010 Feb 20. — View Citation

Levine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013 Dec;10(12):3121-8. doi: 10.1111/jsm.12334. Epub 2013 Oct 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Calcium volume of penile plaques Peyronie plaques with calcification can be identified with noncontrast CT. The Agatston calcium scoring software is used to mark the calcified plaques to measure the calcium volume (mm3) Baseline
Primary Calcium score of penile plaques Peyronie plaques with calcification can be identified with noncontrast CT. The Agatston calcium scoring software is used to mark the calcified plaques to calculate the Agaston calcium score Baseline
Primary Treatment plans adjustment after CT Number of treatment plans to be adjusted after CT results. The treatment options for Peyronie's disease are observation, penile traction therapy, oral medication, medication injection, plaque incision, plaque excision, penile plication with graft, penile plication without graft, penile implant with plaque incision and graft, or penile implant with plication. The study urologist plan will be documented before CT results. After CT results the study urologist will or will not adjust the treatment plan. Within 2 weeks of intervention
Secondary Calcified plaque number Peyronie plaques with calcification can be identified with noncontrast CT and with PDDU. The number of calcified plaques (1, 2, 3 or more than 3) will be counted on CT and PDDU. Baseline
Secondary Calcified plaque length Peyronie plaques with calcification can be identified with noncontrast CT and with PDDU. The plaque will be measured in the longest axial and transverse dimensions (mm) on CT and on PDDU. Baseline
Secondary Calcified plaque continuity Peyronie plaques with calcification can be identified with noncontrast CT and with PDDU. The plaque will be described as continuous or stippled on CT and PDDU by visual assessment Baseline
See also
  Status Clinical Trial Phase
Completed NCT03774264 - Treatment Response to Xiaflex for Men With Peyronie's Disease
Recruiting NCT05777031 - Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease Phase 4
Active, not recruiting NCT05871177 - Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD) N/A
Recruiting NCT05768867 - French Translation and Validation of the PEYronie's Disease QUESTionnaire
Recruiting NCT04512287 - PRP for Treatment of Peyronie's Disease Phase 2
Withdrawn NCT05646602 - Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction N/A
Recruiting NCT03530540 - Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. N/A
Completed NCT04052217 - Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse N/A
Recruiting NCT06303661 - Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease N/A
Recruiting NCT06065436 - Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease N/A
Recruiting NCT05316714 - Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment N/A
Completed NCT04370652 - Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum
Recruiting NCT04821115 - Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease N/A